Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nong Yang

Showing results (71-80 of 208) with videos related to

Pageof 21
Sort By:
Communications Medicine|November 9, 2022
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancerLianxi Song, Liang Zeng, Huan Yan, et al.
Frontiers in Oncology|November 28, 2022
PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world studyZhe Huang, Chunhua Zhou, Yi Xiong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2020
Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination TherapyYubo Wang, Nong Yang, Yongchang Zhang, et al.
Oncotarget|March 5, 2016
A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphomaXueying Li, Xiaojie Fang, Su Li, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 27, 2021
Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteersJianfu Heng, Qi Tang, Xue Chen, et al.
Targeted Oncology|January 25, 2021
A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic CancersJian Zhang, Nong Yang, Dongmei Ji, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 19, 2022
Corrigendum to ' Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers'[European Journal of Pharmaceutical Sciences 162 (2021) 105815]Jianfu Heng, Qi Tang, Xue Chen, et al.
BMC Cancer|August 3, 2024
Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterationsHaoyue Qin, Huan Yan, Yangqian Chen, et al.
Translational Lung Cancer Research|May 9, 2022
The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort studyWenjuan Jiang, Yuling Zhou, Liang Zeng, et al.
Cancer|August 31, 2025
Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancerLong Huang, Fanxu Zeng, Peng Huang, et al.
Pageof 21

Showing results (71-80 of 208) with videos related to

Sort By:
Pageof 21
Communications Medicine|November 9, 2022
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancerLianxi Song, Liang Zeng, Huan Yan, et al.
Frontiers in Oncology|November 28, 2022
PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world studyZhe Huang, Chunhua Zhou, Yi Xiong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2020
Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination TherapyYubo Wang, Nong Yang, Yongchang Zhang, et al.
Oncotarget|March 5, 2016
A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphomaXueying Li, Xiaojie Fang, Su Li, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 27, 2021
Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteersJianfu Heng, Qi Tang, Xue Chen, et al.
Targeted Oncology|January 25, 2021
A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic CancersJian Zhang, Nong Yang, Dongmei Ji, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 19, 2022
Corrigendum to ' Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers'[European Journal of Pharmaceutical Sciences 162 (2021) 105815]Jianfu Heng, Qi Tang, Xue Chen, et al.
BMC Cancer|August 3, 2024
Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterationsHaoyue Qin, Huan Yan, Yangqian Chen, et al.
Translational Lung Cancer Research|May 9, 2022
The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort studyWenjuan Jiang, Yuling Zhou, Liang Zeng, et al.
Cancer|August 31, 2025
Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancerLong Huang, Fanxu Zeng, Peng Huang, et al.
Pageof 21